Effects of dalfampridine on mobility in the context of daily life
- Conditions
- Motor behaviour and cognition in multiple sclerosis patientsTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- EUCTR2014-003498-41-AT
- Lead Sponsor
- Medical University of Vienna
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Patients over 18 years with multiple sclerosis and an EDSS between 4 and 7, suffering from gait disturbance will be included. Only patients who have been identified as responders during a previous named patient programme and were refused to get reimbursement by the public health care system in Austria will be included.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 51
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion criteria will be a treatment with Fampridine less then 6 weeks before the start of the study, previously identified non-response to Fampridine and an age below 18 years.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method